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ABSTRACT
Objective: To evaluate the effect of lymph-vascular space invasion (LVSI) on location of 
recurrences in Danish patients with endometrial cancer.
Methods: This national cohort study (2005–2012) included 4,380 radically operated patients 
(no visual tumor, all distant metastasis removed). LVSI status was recorded in 3,377 (77.1%). 
In stage I patients, 2.6% received adjuvant radiotherapy and 1.4% adjuvant chemotherapy. 
Adjusted Cox regression was used to compare actuarial recurrence rates.
Results: LVSI was present in 18.7% of 3,377 patients with known LVSI status. Of these, 7.6% 
stage I patients with LVSI experienced an isolated locoregional and 19.4% a non-locoregional 
recurrence. Compared to no LVSI, 5-year recurrence rate was higher (25.5% vs. 8.5%) in 
patients with LVSI and the frequency of distant recurrences was strikingly higher (stage I: 
15.2% vs. 2.7%), the effect being similar across International Federation of Gynecology and 
Obstetrics stages and histological types. In intermediate-risk stage I patients with LVSI, 8.0% 
experienced an isolated locoregional recurrence compared to 20.1% with non-locoregional 
recurrence, giving these patients a seriously adverse risk of survival. A separate analysis in 
patients with recurrences demonstrated that those with LVSI had significantly more distant 
recurrences (55.4% vs. 29.9%) and fewer isolated vaginal recurrences (24.3% vs. 42.8%) than 
patients with no LVSI.
Conclusion: LVSI is a strong independent risk factor for the development of non-locoregional 
recurrences even in intermediate-risk stage I endometrial cancer. The non-locoregional 
recurrence pattern suggests a future focus for optimization of postoperative treatment in 
these patients.
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INTRODUCTION
The presence of lymph-vascular space invasion (LVSI) in endometrial cancer has been 
demonstrated to be significantly and independently associated with poor outcome. LVSI has 
been associated with decreased survival [1-7] and increased risk of disseminated disease at 
time of diagnosis [8], including pelvic and paraaortic lymph node (LN) metastasis [7,9-12]. 
Moreover, the risk of recurrence also seems to be increased in these patients [2,4-6,8,13].
LVSI is incorporated into the European Society for Medical Oncology/European Society of 
Gynaecological Oncology/European Society for Radiotherapy & Oncology risk stratification 
system, and non-staged LVSI-positive intermediate-risk stage I patients are recommended 
adjuvant external beam radiation therapy (EBRT) to decrease locoregional recurrence. 
However, no treatment is suggested that may have an effect on the risk of distant recurrences 
[14]. Recommendations are based on limited data on recurrence patterns in small studies 
[2,15-18] with a limited number of patients with LVSI (66 to 129 cases), which does not 
allow drawing safe conclusion with respect to risk stratification (stage, tumor type, and 
risk stratification in stage I disease). Therefore, knowledge of the pattern of recurrences in 
different stage and risk groups of tumors is an important determinant for the type of adjuvant 
therapy offered LVSI cases.
The Danish Gynecological Cancer Database (DGCD) covers all endometrial cancers [19]. 
Danish stage I patients have traditionally rarely been given postoperative radiotherapy; 
therefore, this gives a unique opportunity to monitor the pattern of recurrence over time 
in a population less likely to be biased due to the treatment given. The aim of the present 
study was to evaluate in detail the recurrence patterns of Danish endometrial cancer patients 
in relation to LVSI to help tailor future research regarding the indications and choice of 
postoperative adjuvant therapy.
MATERIALS AND METHODS
The validated DGCD 2005–12 includes all 4,706 prospectively registered endometrial cancers 
(excluding sarcomas and carcinosarcomas) diagnosed from 2005 to 2012 [19,20]. Of these, 
190 patients did not undergo hysterectomy, leaving 4,516 patients to be included in the 
analysis of survival in the present study. For analysis of recurrence rates, another 136 non-
radically operated patients with progression were excluded (non-radical defined as residual 
macroscopic tumor in the abdomen or distant metastasis not removed).
Because reporting was optional, LVSI status was primarily registered in only 1,944 cases; 
therefore, the pathology report of the remaining 2,573 case was retrieved from the pathology 
registry. LVSI (yes or no) was described in 1,519 cases and entered into the database, but for 
1,053 cases, LVSI was not described and therefore registered as unknown, giving altogether 3,463 
patients with known LVSI status. LVSI was defined as the presence of tumor cells in a space lined 
by endothelial cells outside the immediate invasive border and included tumor invasion in both 
lymph and blood vessels. Pathologists specialized in gynecological cancers evaluated 70% of all 
cases; the remaining 30% were evaluated by general gynecological pathologists.
As International Federation of Gynecology and Obstetrics (FIGO) stage changed during 
the study period, all patients were reclassified to FIGO 2009 using the data reported by the 
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pathologist. Patients were divided into cases with known LVSI, no LVSI, and unknown LVSI. 
Patients were further subdivided into endometrioid and non-endometrioid tumors (clear cell, 
serous, and undifferentiated carcinoma defined as >10% of the special tumor type). Stage 
I cases were divided into 3 risk groups: 1) low-risk (grades 1 and 2 with <50% myometrial 
invasion), 2) intermediate-risk (grades 1 and 2 with >50% myometrial invasion or grade 3 
with <50% myometrial invasion), and 3) high-risk (grade 3 with >50% myometrial invasion or 
non-endometrioid (clear cell, serous, and undifferentiated carcinoma if >10% of the tumor). 
We also examined separately the stage I patients in whom LNs were staged.
Registration and treatment of endometrial cancers in Denmark is performed according 
to uniform, strictly respected guidelines, and endometrial cancer treatment at each 
gynecological oncology center is annually evaluated with respect whether treatment has been 
according to these guidelines. The operating gynecologist did the primary registration of 
the surgical treatment. Patients were offered abdominal hysterectomy (radical hysterectomy 
for stage II and bilateral salpingo-oophorectomy, peritoneal washings, and intraabdominal 
assessment in all cases. Omentectomy was carried out in high-risk patients, and routine 
pelvic lymphadenectomy was recommended for all intermediate- and high-risk patients, 
taking into account comorbidity and high age. Some institutions routinely undertook 
paraaortic lymphadenectomy for high-risk cases, and all institution removed macroscopically 
enlarge paraaortic LNs.
Using uniform guidelines, the pathologists reported the following: histopathology types; 
grade of tumor; myometrial invasion (no invasion, more or less than 50%); involvement of 
cervix (glandular/stromal invasion), parametrium, vagina, ovaries, tubes, omentum; and 
number of pelvic and paraaortic LNs including number of metastatic nodes. Disease stage 
and risk group were reported as well as presence of tumor cells in washings.
Low- and intermediate-risk stage I cases were given no further therapy, but offered 5-years 
follow-up (every 3–6 months for 3–5 years). No patients received brachytherapy. EBRT 
was recommended for high-risk stage I patients until 2010 (mainly 50 Gy in 27 fractions) 
but was seldom given (14.1%). High-risk cases were offered participation in the ongoing 
European Network for Gynaecological Oncological Trial Groups' protocol (29 patients) or 
5-years follow-up with no further treatment. Stage III–IV cases were referred to an oncology 
department for 6 series of adjuvant chemotherapy (CT), mainly carboplatin-paclitaxel, and 
rarely a combination of EBRT and CT.
Missing data in the DGCD were retrieved from patients' medical records and pathology 
reports using the Danish pathology database (a mandatory, nationwide database). Deaths 
were retrieved from the Danish Central Person Register, which contains information on all 
Danish residents (death and emigration). Death certificates were acquired from the cause 
of death register of the Danish National Board of Health, and cause of death was further 
checked in the medical records. All histologically verified recurrences (n=568) were obtained 
from the pathology database, and another 90 non-histologically verified recurrences 
identified by checking the medical record of patients that had subsequently died. All but 2 
non-histologically verified recurrences died from their disease (1 cured by radiotherapy for 
vaginal recurrence without prior histological verification and another alive 6 years after full 
remission from positron emission tomography-verified LN and bone metastases; this latter 
case is doubtful, but included as not to underestimate recurrences rates).
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Medical records were reviewed for patients with known recurrences to retrieve site, time, 
and treatment of recurrences. For the analysis of recurrence patterns, we excluded 136 
patients with progressive disease at time of primary surgery (not radically operated or 
distant metastasis not removed). Details regarding the locations of the 657 recurrences 
were based on both imaging reports and patient files in 264 patients, physicians' 
descriptions in patient files in 381 patients, but for the remaining 12 recurrences, 
information was derived solely from the pathology reports. These 12 cases may have had 
unregistered additional recurrences.
Actuarial recurrences rates were used to compensate for differences in survivals between 
groups. Recurrences were divided into locoregional, including vaginal and pelvic recurrences 
(pelvic LNs, local spread to rectum, and bladder), and non-locoregional, abdominal (ascites 
and carcinomatosis; involvement of bowel, omentum, and paraaortic LNs), and distant 
recurrences (lung, liver, bone, brain, and LNs other than pelvic and paraaortic) [21]. To 
evaluate the number of isolated locoregional recurrences, recurrences were also divided 
into isolated locoregional (vaginal/pelvic), isolated non-locoregional (abdominal/distant), 
or both locoregional and non-locoregional recurrences. LN recurrences were divided into 
locoregional including pelvic and paraaortic LNs and extra-abdominal LNs including 
(inguinal, mediastinal, neck, and axillar).
Data were analyzed using Stata 11 (StataCorp LLC, College Station, TX, USA) [22]. Kaplan–
Meier estimates and actuarial recurrence rates were used to compute survival and recurrence. 
In all, 11 of 4,516 patients had left Denmark and were lost to follow-up. Causes of death 
other than endometrial cancer were censored for the analysis of disease-specific survival. 
Recurrence-free survival was estimated using time from surgery to first recurrence, censoring 
patients dying from causes other than endometrial cancer. Student's t-test was used to 
calculate differences between means, and the Person χ2 differences between categorical 
parameters. Differences between survivals and actuarial recurrence rates were calculated 
using unadjusted and adjusted Cox regression analysis after adjustment for unknown LVSI 
status. The following patient characteristics were included in the analysis: LVSI status (no 
LVSI, LVSI, unknown LVSI), age (20–59, 60–69, 70–79, and over 80), American Society of 
Anesthesiologists physical status (1, 2, 3–4, and unknown 8 patients), stage, grade (grades I, 
II, III, serous, clear, and undifferentiated), LN resection (yes/no), and adjuvant therapy with 
EBRT (yes/no) or CT (yes/no) as categorical parameters. As the groups no LVSI and LVSI were 
different with respect to confounders, we also performed propensity-score matching on the 
entire population for overall, cancer-specific and recurrence-free survival with results similar 
to those obtained using Cox regression analysis.
No approval from The Danish Ethics Committees was needed. The study was approved by 
the Danish Data Protection Board (No. 2010-41-4627) and by the Danish health authorities 
(No. 3-3013-297/1/).
RESULTS
The mean observation time for survival was 9.2±2.2 years. For recurrences, observation 
time was at least 5 years. Characteristics of the included patients in relation to LVSI are 
given in Table 1. Adjuvant therapy was given to 16.6% (6.9% EBRT, 9.0% CT, and 0.55% 
both) of all 4,516 patients and 3.9% of 3,426 final stage I patient (EBRT/CT: low-risk, 
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1.2%/0.4%; intermediate-risk, 2.3%/1.1%; and high-risk, 14.1%/9.8%). Only 25 patients had 
combined chemo-radiation (high-risk: 2/306 patients; stage II: 2/461 patients; stage IIIA/B 
7/292 patients; stage IIIC: 10/210 patients; and stage IV: 4/127 patients). LN resection was 
performed in 28.9% of all cases and in 22.4% of stage I (low-risk: 9.4%; intermediate-risk: 
41.2%; and high-risk: 63.7%).
1. Recurrences
Five-year recurrence rates are related to LVSI status in Table 2. A significantly higher 5-year 
recurrence rate in LVSI-positive (all: 39.0%; stage I: 25.5%) compared to LVSI-negative 
cases (all: 10.3%; stage I: 8.5%) was demonstrated. This difference meant that the risk of 
recurrences was more than double in LVSI-positive cases for both all patients (stage I–IV) 
and for stage I patients only. However, most markedly the recurrence patterns were clearly 
different between patients with LVSI and those with no LVSI, with a strikingly higher 
frequency of especially distant recurrence and a tripled risk in patients with LVSI compared 
to no LVSI cases (all: hazard ratio [HR]=3.3, 95% confidence interval [CI]=2.5–4.5, p<0.001; 
stage I: HR=3.7, 95% CI=2.4–5.7; p<0.001). Of all LVSI-positive cases, 19.3% has an isolated 
non-locoregional recurrence (abdominal/distant), 15.5% experienced a simultaneous 
locoregional and non-locoregional recurrence, while only 10.5% of LVSI-positive cases had 
an isolated locoregional recurrence (vaginal/pelvic) compared to 3.3%, 2.6%, 4.7% for LVSI-
negative cases. Moreover, LVSI was an independent prognostic factor for LN recurrence at 
all locations.
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Table 1. Comparison of epidemiological, surgical, and histological characteristics of all 4,516 and for 3,426 stage I Danish endometrial cancer patients in relation 
to LVSI status at final histology
Characteristics All stages Stage I
All No LVSI LVSI Unknown  
LVSI  
status
p-value  
of LVSI vs. 
no LVSI
All No LVSI LVSI Unknown  
LVSI  
status
p-value  
of LVSI vs. 
no LVSI
No. 4,516 2,760 (61.1) 703 (15.6) 1,053 (23.3) 3,426 2,425 (70.8) 306 (8.9) 695 (20.3)
Age (yr) 67.4±10.6 67.1±10.4 68.8±10.7 67.1±10.8 <0.001 66.9±10.4 67.0±10.3 67.9±10.4 66.1±10.6 0.149
BMI 28.5±7.0 28.6±7.0 28.0±6.7 28.8±7.0 0.045 28.9±7.1 28.7±7.0 29.3±7.4 29.5±7.2 0.169
ASA 1.8±0.6 1.8±0.6 1.8±0.7 1.7±0.7 0.020 1.7±0.6 1.8±0.6 1.8±0.7 1.7±1.7 0.266
Histological type <0.001 0.003
Endometrioid 4,035 (89.4) 2,537 (91.9) 562 (79.9) 936 (88.9) 3,196 (93.3) 2,267 (93.5) 272 (88.9) 657 (94.5)
Non-endometrioid 481 (10.7) 223 (8.1) 141 (20.1) 117 (11.1) 230 (6.7) 158 (6.5) 34 (11.1) 38 (5.5)
Risk stratification <0.001 <0.001
Low-risk 2,247 (49.8) 1,658 (60.1) 98 (13.9) 491 (46.6) 2,247 (65.6) 1,658 (68.4) 98 (32.0) 491 (70.7)
Intermediate-risk 873 (19.3) 573 (20.8) 147 (20.9) 153 (14.5) 873 (25.5) 573 (23.6) 147 (48.0) 153 (22.0)
High-risk 306 (6.8) 194 (7.0) 61 (8.7) 51 (4.8) 306 (8.9) 194 (8.0) 61 (19.9) 51 (7.3)
Stages II–IV 1,090 (24.1) 335 (12.1) 397 (56.5) 358 (34.0) - - - -
Nodal staging 1,304 (28.9) 677 (24.5) 322 (45.8) 305 (29.0) <0.001 766 (22.4) 512 (21.1) 111 (36.3) 143 (20.6) <0.001
Pelvic 1,297 (28.7) 673 (24.4) 319 (45.4) 305 (29.0) 764 (22.3) 510 (21.0) 111 (36.3) 143 (20.6)
PA 125 (2.8) 51 (1.9) 40 (5.7) 34 (3.2) 51 (1.5) 37 (1.5) 7 (2.3) 7 (1.0)
Nodal metastasis 231/1,304 (17.7) 39/677 (5.8) 130/322 (40.4) 62/305 (20.3) <0.001 - - - -
Adjuvant therapy
No adjuvant therapy 3,767 (83.4) 2,531 (91.7) 405 (57.6) 831 (78.9) <0.001 3,291 (96.1) 2,357 (97.2) 269 (87.9) 665 (95.7) <0.001
RT 313 (6.9) 110 (4.0) 108 (15.4) 95 (9.0) <0.001 87 (2.5) 39 (1.6) 23 (7.5) 25 (3.6) <0.001
CT 408 (9.0) 111 (4.0) 178 (25.3) 119 (11.3) <0.001 46 (1.3) 28 (1.2) 13 (4.3) 5 (0.7) <0.001
RT+CT 25 (0.55) 7 (0.25) 12 (1.7) 6 (0.6) - 2 (0.06) 1 (0.04) 1 (0.33) - -
Unknown 3 (0.07) 1 (0.04) - 2 (0.19) - - - - - -
Progression 136 (3.0) 15 (0.5) 71 (10.1) 50 (4.7) <0.001 0 - - - -
Death <5 yr 935 (20.7) 390 (14.1) 311 (44.2) 234 (22.2) <0.001 474 (13.8) 294 (12.1) 86 (28.1) 94 (13.5) <0.001
From cancer 530 (11.7) 158 (5.7) 236 (33.6) 136 (12.9) <0.001 172 (5.0) 95 (3.9) 48 (15.7) 29 (4.2) <0.001
From others 405 (9.0) 232 (8.4) 75 (10.7) 98 (9.3) 0.060 302 (8.8) 199 (8.2) 38 (12.4) 65 (9.4) <0.012
Data are shown as mean±standard deviation or number (%). p-values using Pearson's t-test or the χ2 test.
ASA, American Society of Anesthesiologists; BMI, body mass index; CT, chemotherapy; LVSI, lymph-vascular space invasion; PA, paraaortic; RT, radiotherapy.
2. Recurrence rate in subgroups
We further examined whether LVSI was an independent prognostic factor in sub-groups of 
patients with endometrial cancer (Table 3). LVSI was an independent significant predictor 
for risk of recurrence for non-endometrioid as well as endometrioid tumors and for all FIGO 
stages except stage IV. In low-risk stage I patients, both locoregional and non-locoregional 
recurrence was increased in patients with LVSI. Remarkably, for LVSI-positive cases there 
were higher risks of non-locoregional recurrence compared to locoregional recurrence in 
patients with stage I (low- and intermediate-risk), stage II and for endometrioid tumors 
(Tables 2 and 3, Fig. 1). LVSI was also prognostic for LN recurrences in most sub-groups 
(Tables 2 and 3, Fig. 2).
3. Intermediate-risk stage I
In intermediate-risk stage I, 20.4% had LVSI, with a total recurrence rate of 28.1% for 
LVSI-positive cases compared to 11.6% for LVSI-negative cases (Table 3, Fig. 2). LVSI-
positive cases had the highest HR of 4.5 (95% CI=2.6–7.9; p<0.001) for non-locoregional 
recurrences (abdominal/distant), which was almost double the HR compared to the risk 
of locoregional recurrence (HR=2.8; 95% CI=1.7–4.6; p<0.001). In the subgroup (41%) of 
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Table 2. Five-year recurrence rates for all and for stage I patients with LVSI, no LVSI, and unknown LVSI status at final histology
All stages No LVSI LVSI Unknown Unadjusted/adjusted Cox
No. (%) Actuarial (%) No. (%) Actuarial (%) No. (%) Actuarial (%) HR‡ (95% CI)
All patients (n=4,380) 2,745 (62.7) 632 (14.4) 1,003 (22.9)
Total recurrence rate 273 (10.0) 10.3 234 (37.0) 39.0 150 (15.0) 15.4 4.7*/2.2* (1.8–2.6)
All vaginal 140 (5.1) 5.3 98 (15.5) 18.2 80 (8.0) 8.3 3.8*/2.3* (1.8–3.1)
All pelvic 80 (2.9) 3.1 72 (11.4) 14.2 49 (4.9) 5.4 5.0*/2.1* (1.5–3.1)
All abdominal 107 (3.9) 4.2 104 (16.5) 19.7 62 (6.2) 6.7 5.4*/2.1* (1.5–2.8)
All distant 89 (3.2) 3.5 139 (22.0) 25.7 56 (5.6) 6.3 8.7*/3.3* (2.5–4.5)
Site of first recurrence
Isolated locoregional 124 (4.5) 4.7 54 (8.5) 10.5 59 (5.9) 6.2 2.3*/1.5† (1.1–2.2)
Isolated non-locoregional 84 (3.1) 3.3 99 (15.7) 19.3 44 (4.4) 4.9 6.6*/2.2* (1.6–3.1)
Both local & non-locoregional 65 (2.4) 2.6 81 (12.8) 15.5 47 (4.7) 5.2 6.8*/3.0* (2.1–4.3)
Locoregional LN recurrences 81 (3.0) 3.2 101 (16.0) 19.4 49 (4.9) 5.4 6.9*/2.5* (1.8–3.5)
All PL 53 (1.9) 2.1 57 (9.0) 11.1 31 (3.1) 3.4 5.9*/2.3* (1.5–3.5)
All PA 53 (2.0) 2.1 71 (11.2) 14.1 32 (3.2) 3.6 7.4*/2.7* (1.8–4.0)
Extraabdominal LN 32 (1.2) 1.3 44 (7.0) 9.0 14 (1.4) 1.6 7.7*/2.9* (1.7–5.0)
Stage I (n=3,426) 2,425 (70.8) 306 (8.9) 695 (20.3)
Total recurrence rate 201 (8.3) 8.5 74 (24.2) 25.5 59 (8.5) 15.5 3.4*/2.3* (1.7–3.0)
All vaginal 114 (4.7) 4.9 39 (12.8) 14.1 38 (5.5) 8.4 3.1*/2.4* (1.7–3.6)
All pelvic 50 (2.1) 2.2 19 (6.2) 7.3 15 (2.2) 5.4 3.5*/2.7* (1.5–4.7)
All abdominal 69 (2.9) 3.0 32 (10.5) 11.9 22 (3.2) 6.7 4.3*/2.8* (1.8–4.3)
All distant 60 (2.5) 2.7 41 (13.4) 15.2 17 (2.5) 6.3 6.3*/3.7* (2.4–5.7)
Site of first recurrence
Isolated locoregional 104 (4.3) 4.5 20 (6.5) 7.6 28 (4.0) 6.2 1.7†/1.4 (0.8–2.3)
Isolated non-locoregional 57 (2.4) 2.5 26 (8.5) 10.2 16 (2.3) 4.9 4.3*/2.3* (1.4–3.8)
Both local & non-locoregional 40 (1.7) 1.8 28 (9.2) 10.3 15 (2.2) 5.2 6.3*/4.6* (2.7–7.7)
Locoregional LN recurrences 52 (2.1) 2.3 23 (7.5) 8.8 15 (2.2) 5.4 4.0*/2.4* (1.4–4.1)
All PL 31 (1.3) 1.4 13 (4.3) 4.8 9 (1.3) 3.5 3.8*/2.6* (1.3–5.3)
All PA 39 (1.6) 1.7 16 (5.2) 6.3 11 (1.6) 3.6 3.8*/2.1† (1.2–3.9)
Extraabdominal LN 22 (0.9) 1.0 15 (4.9) 5.9 3 (0.4) 1.6 6.3*/4.2* (2.0–8.8)
Recurrences divided into total recurrence rate, isolated locoregional, isolated non-locoregional, or both LN recurrences. Total recurrence rate: number of 
recurrences at each location: vaginal, pelvic, abdominal, or distant recurrences. Isolated locoregional (vaginal+pelvic), isolated non-locoregional (abdominal/
distant). Locoregional LN recurrences (pelvic and aortic LN) and extra abdominal LN (inguinal, mediastinal, neck, and axillar).
CI, confidence interval; HR, hazard ratio; LN, lymph node; LVSI, lymph-vascular space invasion; PA, paraaortic; PL, pelvic lymphadenectomy.
*The p<0.001; †The p<0.05 Cox analysis testing LVSI against no LVSI using unadjusted or adjusted Cox; ‡HR adjusted for unknown LVSI status, age (20–59, 60–69, 
70–79, and over 80), American Society of Anesthesiologists (1, 2, 3–5, and unknown), stage, grade (grade I, II, III, serous, clear, and undifferentiated), LN 
resection and adjuvant therapy with external beam radiation therapy (yes/no) or chemo (yes/no) as categorical parameters. One hundred and thirty-six patients 
with progression excluded from analysis of recurrences.
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intermediate-risk patients that were LN staged and LN-negative (Table 3), LVSI status was 
similarly negatively related to recurrence rate and to recurrence at all locations except for 
extra-abdominal LN recurrence.
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Fig. 1. Five-year recurrence rates of cases with or without LVSI subdivided into endometrioid and non-endometrioid cancers. Recurrences divided into total 
number of recurrences at each location: vaginal, pelvic, abdominal, or distant recurrences. If a patient had recurrences at several sites, the patient can be 
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4. High-risk stage I
In the small group of high-risk stage I patients, 23.9% had LVSI, but the risk of recurrence 
was high for both LVSI-positive (39.8%) and LVSI-negative cases (22.6%). LVSI was associated 
with increased recurrence at all locations, but LVSI was an independently significant 
predictor for only non-local recurrences (Table 3, Fig. 2). The number of patients in this 
group was; however, small, giving lower statistical power.
5. Patients with recurrences
Table 4 shows a comparison between recurrence patterns with regard to LVSI status 
in patients with known recurrences. Patients with LVSI had significantly more distant 
recurrences (stage I: 55.4% vs. 29.9%) and fewer isolated vaginal recurrences (24.3% vs. 
42.8%) compared to patients with no LVSI.
6. Multivariate analysis for risk of recurrences
Supplementary Table 1 in the appendix displays the risk of recurrences in relation to LVSI 
(HR=2.15; 95% CI=1.76–2.62) compared to other variables. Adjuvant CT, but not EBRT, 
seems to decrease the risk of recurrence, but only a limited numbers of selected patients were 
treated, which decreases the value of this finding.
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Table 4. Descriptive analysis of recurrence patterns in patients diagnosed with recurrences with respect to LVSI status
Variables All staged Stage I
No LVSI LVSI No LVSI LVSI
No. 273 234 201 74
Death before 5 yr 154 (56.4) 179* (76.5) 101 (50.3) 51† (68.9)
Death from cancer before 5 yr 142 (52.0) 170* (72.7) 93 (46.3) 48† (64.9)
Total recurrence rate
All vaginal 140 (51.3) 98† (41.9) 114 (56.7) 39 (52.7)
All pelvic 80 (29.3) 72 (30.8) 50 (24.9) 19 (25.7)
All abdominal 107 (39.2) 104 (44.4) 69 (34.3) 32 (43.2)
All distant 89 (32.6) 139* (59.4) 60 (29.9) 41* (55.4)
Site of most severe first recurrence
Vaginal 97 (35.5) 38* (16.2) 86 (42.8) 18† (24.3)
Pelvic 27 (9.9) 16 (6.8) 18 (9.0) 2 (2.7)
Abdominal 60 (22.0) 41 (17.5) 37 (18.4) 13 (17.6)
Distant 89 (32.6) 139* (59.4) 60 (29.9) 41* (55.4)
Loco- and non-locoregional
Isolated locoregional 124 (45.4) 54* (23.1) 104 (51.7) 20* (27.3)
Isolated non-locoregional 84 (30.8) 99† (42.3) 57 (28.4) 26 (35.1)
Both local & non-locoregional 65 (23.8) 81† (34.6) 40 (19.9) 28† (37.8)
Locoregional LN recurrences 81 (29.7) 101† (43.2) 52 (25.9) 23 (31.1)
All PL 53 (19.4) 57 (24.4) 31 (15.4) 13 (17.6)
All PA 53 (19.4) 71† (30.3) 39 (19.4) 16 (21.6)
Both PL and PA 25 (9.2) 27 (11.5) 18 (9.0) 6 (8.1)
Extra abdominal LN 32 (11.7) 44† (18.8) 22 (11.0) 15† (20.3)
Values are presented as number (%). Analysed for all patients and for stage I patients separately. Recurrences 
divided into total recurrence rate, site of most severe first recurrence, loco- and non-locoregional recurrences, 
and LN recurrences. Total recurrence rate: number of recurrences at each location: vaginal, pelvic, abdominal, or 
distant recurrences. Site of most severe first recurrence in the order distant>abdominal>pelvic>vaginal. Isolated 
locoregional (vaginal+pelvic), isolated non-locoregional (abdominal/distant) or both locoregional LN recurrences 
PL and PA LN and extra abdominal LN (inguinal, mediastinal, neck, and axillar).
LN, lymph node; LVSI, lymph-vascular space invasion; PA, paraaortic; PL, pelvic lymphadenectomy.
*The p<0.001; †The p<0.05 using the χ2 test. One hundred and thirty-six patients with progression excluded from 
analysis of recurrences.
7. Survivals
Compared with no LVSI, patients with LVSI had a significantly lower overall, disease-specific 
and recurrence-free survival (adjusted HR approximately 2), and this was true for both 
endometrioid and non-endometrioid tumors (Supplementary Fig. 1). For stage I, LVSI was a 
significant prognostic predictor for survival in all 3 risk groups except with regard to cancer-
specific and recurrence-free survival in high-risk patients, but the number of patients in this 
group was small (61 with LVSI of 255 with known LVSI status), giving lower statistical power 
(Supplementary Fig. 2).
DISCUSSION
In this national cohort, the presence of LVSI in endometrial cancer was an independent 
adverse predictor for the risk of developing recurrences in patients with all stages of disease 
and in endometrioid as well as in non-endometrioid tumors. The recurrence pattern for 
patients with LVSI was clearly different from that in patients with no LVSI, patients with LVSI 
having a high-risk of non-locoregional recurrences. Thus, in stage I low- and intermediate-
risk patients, the presence of LVSI 4-doubled the risk of non-locoregional recurrences 
(abdominal/distant). A separate analysis of the recurrence patterns in patients with 
recurrences demonstrated that patients with LVSI had significantly more distant recurrences 
(stage I: 55.4% vs. 29.9%) and fewer isolated vaginal recurrences (24.3% vs. 42.8%) than 
patients with recurrence and no LVSI. The very high-risk of non-local recurrences in patients 
with LVSI is the main finding in the present study and needs to be considered when advising 
adjuvant treatment to this group of patients.
LVSI was presented in a considerable proportion (20.4%) of stage I intermediate-risk 
patients. In these patients, 28% had recurrences (20% non-locoregional (abdominal/distant) 
and only 8% isolated local recurrence), demonstrating that non-local recurrences are the 
most serious adverse risk of survival in patients with LVSI.
The major strengths of the present study are inclusion of an entire population, the high 
number of LVSI cases (n=703), and loss of only 11 of 4,516 patients followed up, thereby giving 
reliable recurrence and survival data. A further advantage is the Danish centralization of cancer 
treatment and the vast registration of data that enabled us to also have valid data on the location 
of recurrences. Tissue pathology was reported by a pathologist specialized in gynecological 
oncology in 70% of cases, ensuring highly accurate reports in the majority of cases.
A clear limitation of the present study is that 23% of cases had unknown LVSI status, which 
may have introduced selection bias. The number of cases with unknown LVSI status is, 
however, similar in the different histological subgroups and in the 3 different risk groups of 
stage I disease. The missing LVSI information is almost completely due to a period during 
which documentation of LVSI was voluntary, and some pathologists, including specialized 
pathologists, did not report LVSI status. Because the survival of the unknown cases is situated 
between the no LVSI and with LVSI cases, indicating that the group contains a mixture of 
cases, the group is considered comparable with the other groups. We acknowledge that 
data may have been less accurate with regard to the site of multiple metastases in the same 
patient because histological verification was not performed at all locations, and the site of 
metastasis therefore mainly relied on surgeons' or oncologists' descriptions of image reports. 
Not all patients had nodal staging, and some patients might have been understaged. However 
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separate analysis of woman with nodal staging only changed the risk marginally. Another bias 
is the lack of differentiation between lymphovascular and blood vessel invasion in accordance 
with traditional pathological assessment [23]. Modern immunohistochemistry methods 
now allow differentiation between lymph vessels and blood vessels [8,15]. A recent study, 
examining 66 cases with vessel invasion, indicates that patients with tumor invasion into 
lymph vessels more often have LN metastasis at primary diagnosis, whereas cases with tumor 
invasion into blood vessels seem to have a higher risk of distant recurrences (12 cases). Future 
research should be dedicated to finding pathological/biomarkers, including refinement of the 
diagnosis of LVSI and differentiation between tumor invasion into blood and lymph vessels to 
predict risk of recurrences and guide the indication for and the type of postoperative therapy 
offered individual endometrial cancer patients [15].
The present study supports the vast literature demonstrating that the present of LVSI in 
endometrial cancer is an independent adverse predictor for overall, cancer-specific and 
recurrence-free survival [1,2,4,6,7,13]. To our knowledge, only a few small studies (66 to 
129 LVSI cases) have previously examined the specific location of recurrences in patients 
with LVSI [2,15-18]. One of the largest studies examined 129 LVSI-positive cases among 926 
patients with endometrioid stage I cancers, mainly intermediate-risk, but only 13 LVSI-
positive cases received no postoperative adjuvant therapy. The authors demonstrated that 
substantial LVSI (44 patients) was the strongest independent prognostic factor for pelvic 
and distant recurrences [2]. In the present large cohort, these findings were confirmed 
for stage I intermediate-risk patients. In addition, with regard to the specific location of 
recurrences, we noted the special high-risk (HR=4.5) of non-local recurrences in mainly 
non-irradiated LVSI cases.
Endometrial cancer patients have traditionally been given postoperative EBRT to decrease 
vaginal and pelvic recurrences. One could argue that the increased risk in non-local 
recurrences found in the present study could also be a result of the Danish practice of not 
giving postoperative radiotherapy. Studies of post-operative radiation therapy in endometrial 
carcinoma have; however, demonstrated that while EBRT or vaginal brachytherapy reduces 
locoregional recurrences, the number distant recurrences and the recurrence-free survival 
are unaffected by the treatment given intermediate- and high-risk patients [24-27]. In 
Danish historical data, we found that the risk of recurrences seems to increase after all 
types of radiotherapy was omitted for intermediate-risk due to an increase in locoregional 
recurrences, while in a small group of high-risk patients, no effect on number of locoregional 
or non-locoregional recurrences could be detected after radiotherapy was omitted [21,28]. 
In the pioneer study of Alders et al. [26] on EBRT for stage I patients, the authors found a 
decrease in locoregional recurrences, but also a marginal, but non-significant, increase in 
distant recurrences, which explains the unchanged recurrence-free survival in patients given 
compared with patients not given radiotherapy. A plausible explanation for this could be 
that vaginal recurrence occur sooner then distant recurrence [21,29], and as many patients 
experience multiple sites of recurrences, the first recurrences may shift from vaginal to 
distant if the vaginal recurrence is prevented by radiotherapy.
Newer studies have, however, indicated that for endometrial cancers patients with a high-risk 
of recurrence, adjuvant CT may also reduce the risk of distant recurrences [15,30]. In a prior 
study, EBRT decreased pelvic but not distant recurrence in patients with LVSI, while vaginal 
brachytherapy did not affect pelvic recurrence, and EBRT and/or CT was suggested [2]. In the 
present study, only a small group of selected women had adjuvant treatment, but CT seemed 
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to decrease recurrence, while EBRT did not. However, the findings in the present study, with 
a high proportion of LVSI-positive cases experiencing non-locoregional recurrences, probably 
due to the fact that LVSI also includes blood vessel invasion, indicate that local treatment 
is not sufficient in intermediate- and high-risk stage I cases, and future studies should be 
dedicated toward finding other treatment regimens that can reduce the risk of developing 
both locoregional and non-locoregional recurrences.
In conclusion, non-locoregional recurrences are the most serious adverse risk for survival 
in endometrial cancer cases with LVSI, and research into effective postoperative systemic 
adjuvant therapy should be initiated.
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